A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients

Psychopharmacology

Volumn 230, Issue 1, 2013, Pages 3-13

  Hu, Shaohua ^a   Yao, Mingrong ^b   Peterson, Bradley S ^c   Xu, Dongrong ^c   Hu, Jianbo ^a   Tang, Jianliang ^b   Fan, Bing ^c   Liao, Zhengluan ^d   Yuan, Tianyi ^b   Li, Yaling ^b   Yue, Weiqing ^b   Wei, Ning ^a   Zhou, Weihua ^a   Huang, Manli ^a   Xu, Yi ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Kangci Hospital of Jiaxing   (China)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^d ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Antipsychotic; Insulin resistance; Metabolic syndrome; Olanzapine; Paliperidone; Cell function

Indexed keywords

ALPRAZOLAM; CHOLESTEROL; ESTAZOLAM; GLUCOSE; GLYCOHEMOGLOBIN A1; GLYCOSYLATED HEMOGLOBIN; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; PALIPERIDONE; PROLACTIN; PROPRANOLOL; TRIACYLGLYCEROL; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG;

ADULT; AGITATION; ANXIETY; ARTICLE; BEHAVIOR DISORDER; BODY MASS; BODY WEIGHT; CELL FUNCTION; CONSTIPATION; CONTROLLED STUDY; DIET RESTRICTION; DIZZINESS; DRUG EFFECT; DRUG FORMULATION; DRUG WITHDRAWAL; DSM-IV; ECG ABNORMALITY; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FEMALE; GLUCOSE METABOLISM; HIP CIRCUMFERENCE; HOMEOSTASIS; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HUMAN CELL; HYPERKINESIA; INSOMNIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MUSCLE HYPERTONIA; NAUSEA; ORTHOSTATIC HYPOTENSION; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; SUBCUTANEOUS FAT; TACHYCARDIA; TREATMENT DURATION; VOMITING; WAIST CIRCUMFERENCE; XEROSTOMIA;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; BODY WEIGHT; DELAYED-ACTION PREPARATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; ISOXAZOLES; LIPID METABOLISM; MALE; PROSPECTIVE STUDIES; PYRIMIDINES; SCHIZOPHRENIA; TIME FACTORS; YOUNG ADULT;

EID: 84886245802     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3073-1     Document Type: Article

References (57)

1. Asakawa A, Inui A, Kaga T, Yuzuriha H, Nagata T, Ueno N, Makino S, Fujimiya M, Niijima A, Fujino MA, Kasuga M (2001) Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 120:337-345
2. Bergman RN, Ader M (2005) Atypical antipsychotics and glucose homeostaiss. J Clin Psychiatr 66:504-514
3. Berwaerts J, Cleton A, Rossenu S, Talluri K, Remmerie B, Janssens L, Boom S, Kramer M, Eerdekens M (2010) A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. J Psychopharmacol 24:1011-1018
4. Buse JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L (2003) A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 56:164-170
5. Calarge CA, Acion L, Kuperman S, Tansey M, Schlechte JA (2009) Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. J Child Adolesc Psychopharmacol 19:101-109
6. Caro JJ, Ward A, Levinton C, Robinson K (2002) The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatr 63:1135-1139
7. Citrome L (2003) Evaluation of obesity. Who are the obese? Postgrad Med 114:19-38
8. Citrome L, Jaffe A, Levine J, Allingham B, Robinson J (2004) Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv 55:1006-1013
9. David SR, Taylor CC, Kinon BJ, Breier A (2000) The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 22:1085-1096
10. Davidson M, Emsley R, Kramer M, Ford L, Pan G, Lim P, Eerdekens M (2007) Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 93:117-130
11. Fatemi SH (2006) Olanzapine increases glucogenesis by multiple pathways in brain and muscle. Mol Psychiatr 11:524-525
12. Fern J, Raeder MB, Vik-Mo AO, Skrede S, Glambek M, Tronstad KJ, Breilid H, Lvlie R, Berge RK, Stansberg C, Steen VM (2005) Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics J 5:298-304
13. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM (2007) Metabolic syndrome and risk of incidentcardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 49:403-414
14. Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L, Poraz I, Frishman S, Constantini N, Zalsman G, Weizman A, Apter A (2002) Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 159:1055-1057
15. Haffner SM, Miettinen H, Stern MP (1997) The homeostasis model in the San Antonio Heart Study. Diabetes Care 20:1087-1092
16. Isaac MB, Isaac MT (2005) Olanzapine and weight gain. Am J Psychiatry 162:1764-1765
17. Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M (2007) Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 90:147-161
18. Karlsson P, Dencker E, Nyberg S, Mannaert E, Boom S, Talluri K, Rossenu S, Eriksson B, Eerdekens M, Farde L (2005) Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects (Abstract). Eur Neuropsychopharmacol 15(Suppl 3):S385
19. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH (2007) From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A 104:3456-3459
20. Kramer M, Simpson G, Maciulis V, Kushner S, Vijapurkar U, Lim P, Eerdekens M (2007) Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 27:6-14
21. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28:519-526
22. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223
23. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy J, Cooper T, Chakos M, Lieberman J (2003) Changes in glucose and cholesterol levels in patient with schizophrenia treated with typical and atypical antipsychotics. Am J Psychiatry 160:290-296
24. Lohman TG, Roche AF, Martorell R (1988) Anthropometric standardization reference manual. Human Kinetics Books, Champaign, IL
25. Maguire GA (2002) Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatr 63:56-62
26. Mannens G, Meuldermans W, Snoeck E, Heykants J (1994) Plasma protein binding of risperidone and its distribution in blood. Psychopharmacology (Berl) 114:566-572
27. Marder SR, Davis JM, Chouinard G (1997) The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatr 58:538-546
28. Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, Lowy A (2007) Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 62:1363-1670
29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
30. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Stroup TS, Lieberman JA (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80:19-32
31. Megens AAHP, Awouters FHL (1994) In vivo pharmacologic profile of 9-hydroxyrisperidone the major metabolite of the novel antipsychotic risperidone. Drug Dev Res 33:399-412
32. Meguid MM, Fetissov SO, Varma M, Sato T, Zhang L, Laviano A, Rossi-Fanelli F (2000) Hypothalamic dopamine and serotonin in the regulation of food intake. Nutrition 16:843-857
33. Melkersson K (2004) Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro. Eur Neuropsychopharmacol 14:115-119
34. Melkersson KI, Hulting AL, Brismar KE (2000) Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatr 61:742-749
35. Meyer JL, Stahl SM (2009) The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 119:4-14
36. Meyer J, Davis V, Goff D, McEvoy J, Nasrallah H, Davis S, Rosenheck R, Daumit G, Hsiao J, Swartz M, Stroup TS, Lieberman J (2008) Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res 101:273-286
37. Monteleone P, Fabrazzo M, Tortorella A, La Pia S, Maj M (2002) Pronounced early increase in circulating leptin predicts a lower weight gain during clozapine treatment. J Clin Psychopharmacol 22:424-426
38. Newcomer JW (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19:1-93
39. Nielsen J, Skadhede S, Correll CU (2010) Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology 35:1997-2004
40. Nussbaum AM, Stroup TS (2008) Paliperidone for treatment of schizophrenia. Schizophr Bull 34:419-422
41. Peuskens J, Group RS (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 166:712-716
42. Polydoro M, Schroder N, Lima MN, Caldana F, Laranja DC, Bromberg E, Roesler R, Quevedo J, Moreira JC, Dal-Pizzol F (2004) Haloperidol- and clozapine-induced oxidative stress in the rat brain. Pharmacol Biochem Behav 78:751-756
43. Pramyothin P, Khaodhiar L (2010) Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes 17:460-466
44. Reinke A, Martins MR, Lima MS, Moreira JC, Dal-Pizzol F, Quevedo J (2004) Haloperidol and clozapine, but not olanzapine, induces oxidative stress in rat brain. Neurosci Lett 372:157-160
45. 2C receptor gene polymorphism. Lancet 359:2086-2087
46. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S (2010) Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 123:225-233
47. Saddichha S, Manjunatha N, Ameen S, Akhtar S (2008) Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled, short-term prospective study. Schizophr Res 101:266-272
48. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124:57-73
49. Smith RC, Lindenmayer JP, Bark N, Warner-Cohen J, Vaidhyanathaswamy S, Khandat A (2005) Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients. Int J Neuropsychopharmacology 8:183-194
50. Smith RC, Segman RH, Golcer-Dubner T, Pavlov V, Lerer B (2008) Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia. Pharmacogenomics J 8:228-236
51. Smith RC, Lindenmayer JP, Davis JM, Kelly E, Viviano TF, Cornwell J, Hu Q, Khan A, Vaidhyanathaswamy S (2009) Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study. J Clin Psychiatr 70:1501-1513
52. Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R (2002) Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 26:137-141
53. Ukkola O, Ravussin E, Jacobson P, Perusse L, Rankinen T, Tschop M, Heiman ML, Leon AS, Rao DC, Skinner JS, Wilmore JH, Sjostrom L, Bouchard C (2002) Role of ghrelin polymorphisms in obesity based on three different studies. Obes Res 10:782-791
54. Vickers SP, Easton N, Webster LJ, Wyatt A, Bickerdike MJ, Dourish CT, Kennett GA (2003) Oral administration of the 5-HT2C receptor agonist, mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia. Psychopharmacology 167:274-280
55. Walss-Bass C, Weintraub ST, Hatch J, Mintz J, Chaudhuri AR (2008) Clozapine causes oxidation of proteins involved in energy metabolism: a possible mechanism for antipsychotic-induced metabolic alterations. Int J Neuropsychopharmacol 11:1097-1104
56. Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W, Netusil N, Fowler JS (2001) Brain dopamine and obesity. Lancet 357:354-357
57. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946